Ordering Recommendation

Detect exposure to amphetamines.

Mnemonic
AMPS SP
Methodology

Quantitative Liquid Chromatography-Tandem Mass Spectrometry 

Performed

Tue

Reported

1-8 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Gray (sodium fluoride/potassium oxalate). Also acceptable: Plain red, green (sodium heparin), lavender (EDTA), or pink (K2EDTA).

Specimen Preparation

Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Separator tubes. Plasma or whole blood collected in lt. blue (sodium citrate). Specimens exposed to repeated freeze/thaw cycles. Hemolyzed specimens.

Remarks
Stability

After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years

Reference Interval

Effective August 17, 2015

Drugs Covered Cutoff Concentrations
Amphetamine 20 ng/mL
Methamphetamine 20 ng/mL
Methylenedioxyamphetamine (MDA) 20 ng/mL
Methylenedioxymethamphetamine (Ecstasy, MDMA) 20 ng/mL
Methylenedioxyethylamphetamine (Eve, MDEA) 20 ng/mL

Interpretive Data

Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry 

Positive cutoff:
20 ng/mL

For medical purposes only; not valid for forensic use.

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory. 

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
Hotline History
N/A
CPT Codes

80324; 80359 (Alt code: G0480)

Components
Component Test Code* Component Chart Name LOINC
2010068 Amphetamine, S/P, Quant 30112-7
2010069 Methamphetamine, S/P, Quant 3778-8
2010070 MDA, S/P, Quant 59837-5
2010071 MDMA, S/P, Quant 18356-6
2010072 MDEA, S/P, Quant 33016-7
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Adderall
  • Amphetamine
  • Benzedrine
  • Carbex
  • Deprenyl
  • Desoxyephedrine
  • Desoxyn
  • Dexedrine
  • Dextroamphetamine
  • Ecstasy
  • Eldepryl
  • Emsam
  • Eve
  • Lisdexamfetamine
  • MDA
  • MDEA
  • MDMA
  • Methamphetamine
  • Methedrine
  • Pain Management
  • Paremyd
  • Selegiline
  • Vicks Inhaler
  • Vynase
  • XTC
  • Zelapor
Amphetamines, Serum or Plasma, Quantitative